Sign in

Michael S. Balzer

@balzer-lab.org
1.3K followers 2.3K following 168 posts

MD FASN | Professor @uni-kiel.de | Nephrologist & #ClinicianScientist | #SingleCell & spatial multiomics | Determined to understand kidney repair to prevent disease progression | #ERCStG | JASN Editorial Board | 🌐 balzer-lab.org

PostsRepliesMedia
Michael S. Balzer @balzer-lab.org · 21/08/2026
Intriguing data from @hjanders.bsky.social: Too much of a good rise?🩸In people w/ CKD starting SGLT2i, Hb climbed for 12 months; erythrocytosis developed in 19.5% of men vs 3.8% of women. At >2,000 m, rapid Hb rise, not the threshold alone, tracked w/ thrombosis. #NephSky 🧪 doi.org/10.34067/KID...
071
Michael S. Balzer @balzer-lab.org · 19/08/2026
Nice integration work of spatial transcriptomics & metabolomics by @trabelink.bsky.social & team in JASN showing that injured kidney niches are characterized by impaired metabolic remodeling. 🧪 doi.org/10.1681/ASN.... #AKI #KidneyResearch #NephSky #MedSky
030
Reposted by Michael S. Balzer
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/06/2026
And FIND CKD is live already on NEJM www.nejm.org/doi/full/10.... #ERA26
nejm.org
Finerenone in Persons with Chronic Kidney Disease without Diabetes | NEJM
In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD)...
2167
Michael S. Balzer @balzer-lab.org · 04/06/2026
🙏Feeling very grateful. Honored to receive the #ERA26 Stanley Shaldon Award from @ERAKidney. Thank you to everyone who has contributed to this journey! Our mission remains to better understand kidney repair/regeneration & translate these discoveries into new therapies for patients🩺🧪 #Nephsky #Medsky
Michael S. Balzer receiving the #ERA26 Stanley Shaldon Award from ERA President Roser Torra.
0112
Michael S. Balzer @balzer-lab.org · 03/06/2026
#ERA26 let‘s gooooo! 🧪 #Nephsky, #Medsky
0100
Michael S. Balzer @balzer-lab.org · 03/05/2026
🚨CONGRATS @ksusztak.bsky.social @bernhard-dumoulin.bsky.social & team on a fantastic @nature.com paper! DKD isn’t 1 disease! #spatial & #singlecell data reveal distinct injury niches—including B cell–rich immune subtype linked to faster progression. #Nephrology #PrecisionMedicine #NephSky #MedSky 🧪
0154
Michael S. Balzer @balzer-lab.org · 21/04/2026
🚨We've moved! Balzer Lab🧪is now in Kiel (UKSH/CAU)🌊 And we're hiring for ERC-funded projects: 1 #Postdoc, 2 #PhD positions (sc/spatial+organoids) 🔬Study how human kidneys adapt to organ loss! 💰Competitive salaries+full benefits 📅Apply by June 1, 2026 balzer-lab.org/news/we-are-... #NephSky #MedSky
balzer-lab.org
We are hiring | BALZER LAB
Open positions in the Balzer Lab at Kiel University and the University Hospital Schleswig-Holstein
030
Michael S. Balzer @balzer-lab.org · 26/02/2026
One kidney. One decision. Multiple lives changed. German Lopez's very personal opinion piece in @nytimes.com on why he donated to a stranger — and why more of us should consider it. 🫘🧪 🔗 www.nytimes.com/2026/02/02/o... #NephSky #MedSky #Science #OrganDonation
nytimes.com
Opinion | Want to Make a Difference? Donate Your Kidney.
060
Michael S. Balzer @balzer-lab.org · 03/02/2026
Classic Fred Luft #Nephrology 101 editorial on a study testing the effect of potassium supplement on natriuresis: Eliminating sodium with potassium 🔗 academic.oup.com/ndt/article/... #NephSky #MedSky 🧪
186
Michael S. Balzer @balzer-lab.org · 08/01/2026
Bottom line: RAAS inhibition not just lowers pressure. It reshapes a pathological conversation btw/ distal nephron & inflammatory macs. And single-cell biology is no longer about making prettier atlases. It is about correcting assumptions we have been carrying for decades. 🧪Paper: t.ly/oNjkJ
t.ly
041
Michael S. Balzer @balzer-lab.org · 08/01/2026
The human data brought it home. Higher CTSD expr. in kidney tubules tracked w/ worse eGFR & more fibrosis. Patients on RAASi had lower CTSD. And a gene signature derived from enalapril-responsive cells stratified kidneys by outcomes, not diagnoses. Mechanism meeting prognosis is always satisfying.
110
Michael S. Balzer @balzer-lab.org · 08/01/2026
Spatial transcriptomics sealed it. In human DKD kidneys, CTSD⁺ connecting tubules and TREM2⁺ macrophages sit next to each other. Not metaphorically. Physically. When disease is present, their neighborhood expands. When RAAS signaling is suppressed, that neighborhood quiets down. Context matters.
110
Michael S. Balzer @balzer-lab.org · 08/01/2026
Then came the immune system. Those CTSD⁺ distal cells were talking — loudly — to a specific macrophage population: TREM2⁺ resident macrophages. These macrophages were inflammatory, expanded in DKD, and shrank with enalapril treatment. This was epithelial–immune crosstalk, not collateral damage.
100
Michael S. Balzer @balzer-lab.org · 08/01/2026
Digging deeper, we found a distinct population of CTSD⁺ connecting tubule cells. They sit between healthy and injured states. Not fully broken, not fully normal. Transitional. Plastic. Vulnerable. And enalapril selectively depleted this population. That was the first “oh wow” moment.
100
Michael S. Balzer @balzer-lab.org · 08/01/2026
One molecule kept showing up: cathepsin D (CTSD). Strongly induced in diabetic kidneys. Strongly suppressed by enalapril. And not everywhere — very specifically in a subset of distal nephron cells. This was not a generic injury marker. It looked like a state.
100
Michael S. Balzer @balzer-lab.org · 08/01/2026
When we mapped the kidney cell by cell, the biggest enalapril “rescue” signal was not in proximal tubules. It was in the distal nephron. That alone made us stop and reread the plots twice.
100
Michael S. Balzer @balzer-lab.org · 08/01/2026
Using long-term enalapril treatment in the ZSF1 rat DKD model, we confirmed the obvious first: blood pressure, albuminuria, fibrosis, injury markers all improved. So yes, the drug works. But where does it work? That question is where single-cell really earns its keep.
100
Michael S. Balzer @balzer-lab.org · 08/01/2026
RAAS inhibitors have been used for decades. We all learned the story: glomeruli, proximal tubules, hemodynamics. But when we looked at this with single-cell resolution, the biology told a different story. Not louder. Just clearer. And it pointed us somewhere unexpected.
110
Michael S. Balzer @balzer-lab.org · 08/01/2026
Excited to share our recent JASN paper on enalapril effects in #DKD using #single-cell approaches.🧪 Thanks to the whole team @nephrointberlin.bsky.social @PennKidney, and @Bayer. Special 🙏 to my mentor @ksusztak.bsky.social. Her insightful X thread is copied below. 🔗 t.ly/oNjkJ #NephSky #MedSky
1111
Michael S. Balzer @balzer-lab.org · 03/01/2026
Check out a recent interesting case of C-H-BG syndrome from @nephrointberlin.bsky.social. A great example of how rare symptoms in a common disease can present with complex phenotypes. #NephSky #MedSky 🧪 🔗 www.sciencedirect.com/science/arti...
094
Michael S. Balzer @balzer-lab.org · 23/12/2025
Merry Xmas! 🎄 Be kind to your kidneys this holiday season. #NephSky #MedSky 🫘🧪
A christmas tree ornament reading "He's making a lith and checking it twice", picturing a kidney with Santa's hat.
041
Reposted by Michael S. Balzer
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 17/12/2025
We really don’t think BigPAK makes sense From our journal club at @uottawa.ca into a #NephJC shorts www.nephjc.com/news/2025/12...
nephjc.com
BigPAK or a bundle of balderdash? — NephJC
We break down the latest salvo from Zarbock et al on a supposedly wonderful ‘bundle’
2125
Reposted by Michael S. Balzer
Jade Teakell, MD @jmteakell.bsky.social · 08/11/2025
Keep Calm & Carry On Inhibiting RAS 👑 #Kidneywk #Nephjc 👉 www.nephjc.com/news/stopacei 👉 www.nephjc.com/news/aceing-...
061
Michael S. Balzer @balzer-lab.org · 07/11/2025
Well deserved, Rafael! Congrats!
000
Michael S. Balzer @balzer-lab.org · 07/11/2025
👏Huge congratulations to my fantastic mentor @ksusztak.bsky.social for receiving the 2025 ASN Homer Smith award.
0192
Michael S. Balzer @balzer-lab.org · 06/11/2025
👏Fantastic to see @cetinsz.bsky.social from our team presenting insights into #single-cell transcriptomic patterns distinguishing recovery from non-recovery after #AKI. Exciting 🧪 at #KidneyWk Houston, TX! #MedSky #NephSky
070
Michael S. Balzer @balzer-lab.org · 06/11/2025
❓Do we finally have a nodular sclerosis mouse model for DKD? 🔥Tour-de-force #kidneywk talk by @linkermannlab.bsky.social suggests so. 🧪 #NephSky #MedSky
182
Reposted by Michael S. Balzer
Javier Santoyo @jsantoyo.bsky.social · 27/10/2025
Cell Decoder: decoding cell identity with multi-scale explainable deep learning. #SingleCellOmics #CellCharacterization #GenomeBiology 🧪🧬 🖥️ genomebiology.biomedcentral.com/articles/10....
022
Reposted by Michael S. Balzer
Physalia-courses@ONLINE @physaliacourses.bsky.social · 07/10/2025
🚀 Curious about #SpatialOmics? Want to master spatial omics data analysis using #Rstats and @bioconductor.bsky.social ? 🔥 Registrations are now OPEN for the 3rd edition of our hands-on course with @stemang.bsky.social ! 📅 Save the dates: 18–20 May 2026 www.physalia-courses.org/courses-work...
physalia-courses.org
spatial Omics in R/Bioconductor
18-20 May 2026 To foster international participation, this course will be held online
043
Michael S. Balzer @balzer-lab.org · 04/09/2025
Thx, Rebecca!
000
Michael S. Balzer @balzer-lab.org · 04/09/2025
Thanks, Tilo! 👍
000
Michael S. Balzer @balzer-lab.org · 04/09/2025
💯👍
000
Michael S. Balzer @balzer-lab.org · 04/09/2025
Thanks, Lennard! 🙏
000
Michael S. Balzer @balzer-lab.org · 04/09/2025
🚀Excited to announce that I’ve been awarded an @erc.europa.eu StG to advance research how kidneys heal themselves — a paradigm shift for understanding & treating #kidneydisease 🫘🩺🧬🧪 👉ERC press release: t.ly/CBxwB 👉Charité press release: t.ly/SR_Wn #ERCStG #HorizonEU #KidneyResearch #NephSky #MedSky
t.ly
The ERC awards €761m to the next generation of scientists in Europe
The European Research Council (ERC) has selected 478 early-career researchers across Europe to receive this year’s Starting Grants. With a total funding of €761 million, these grants support excellent...
5212
Reposted by Michael S. Balzer
Kidney Precision Medicine Project @kpmproject.bsky.social · 15/08/2025
📑 Need something to read this weekend? If so, you're in luck! "Integration of spatial protein imaging and transcriptomics in the human kidney tracks the regenerative potential of proximal tubules" fueled by #KPMP investigators is hot off the press today @science.org www.science.org/doi/10.1126/...
science.org
Integration of spatial protein imaging and transcriptomics in the human kidney tracks the regenerative potential of proximal tubules
The interplay in expression of the stem cell markers THY1 and PROM1 in kidney proximal tubules marks the timeline of disease.
0134
Michael S. Balzer @balzer-lab.org · 08/08/2025
🔥 Huge congrats to @ksusztak.bsky.social & team on a landmark @natgenet.nature.com paper! 🚶‍♂️🐁🐀Cross-species 🫘kidney pathway dysregulation via #singlecell functional profiling of individual samples — opening new therapeutic avenues. 🔗 www.nature.com/articles/s41... 🧪 #NephSky #MedSky
1177
Michael S. Balzer @balzer-lab.org · 20/07/2025
🔥Paper alert @nature.com. Fantastic 🧪resource for the renal 🫘 community! #NephSky #MedSky Congrats @puellesv.bsky.social lab and team!
1151
Reposted by Michael S. Balzer
Nature Reviews Nephrology @natrevneph.nature.com · 18/07/2025
nature.com
Pregnancy-associated acute kidney injury — consensus report of the 32nd Acute Disease Quality Initiative workgroup
Nature Reviews Nephrology, Published online: 18 July 2025; doi:10.1038/s41581-025-00979-6Pregnancy-associated acute kidney injury is a risk factor for maternal and fetal morbidity and mortality and a driver of health inequity worldwide. This Consensus Statement from the Acute Disease Quality Initiative provides recommendations on the causes, diagnosis, management and follow-up of pregnancy-associated acute kidney injury.
096
Reposted by Michael S. Balzer
Kidney International @kidneyint.bsky.social · 07/07/2025
Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy doi.org/10.1016/j.kint.2025.05.028 #OpenAccess #IgAN #felzartamab #IgANephropathy
077
Reposted by Michael S. Balzer
Jan T Kielstein, MD @jtkidney.bsky.social · 05/07/2025
Simon Davies kicking off day 2 of the 1st International Meeting on Cellular and Molecular Peritonial Dialysis Research in Kiel.
041
Michael S. Balzer @balzer-lab.org · 01/07/2025
👏Congrats to the KidneyCure 2025 Grant Recipients! 🫘🧪 @asnpublications.bsky.social #NephSky #MedSky
KidneyCure 2025 Grant Recipients
071
Reposted by Michael S. Balzer
NEJM.org @nejm.org · 21/06/2025
In the latest video in our partnership with @glaucomflecken.bsky.social, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free: nej.md/DrG19
38731
Reposted by Michael S. Balzer
ISPD - International Society for Peritoneal Dialysis @ispd.org · 22/06/2025
The Fellowship Program is one of the ISPD’s key instruments to strengthen global PD expertise through hands-on learning and knowledge exchange. Learn more about the results of our first call for applications in 2025 and the new application modality for teams Doctor-Nurse. buff.ly/7XjuPCM
buff.ly
ISPD Fellowship results - 1st call 2025 - International Society for Peritoneal Dialysis
The Fellowship Program is one of the ISPD’s key programs to strengthen global PD expertise through hands-on learning and knowledge exchange. For the first round of 2025, we received 17…
011
Michael S. Balzer @balzer-lab.org · 07/06/2025
Go Nina! Love the fancy ambience.
110
Reposted by Michael S. Balzer
NEJM.org @nejm.org · 05/06/2025
In the CONFIDENCE trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results: nej.md/4jEVbbk #ERA25 #MedSky #Nephrology
A graph of the least-squares mean ratio of the change from baseline in the urinary albumin-to-creatinine ratio in the full analysis population.
12916
Michael S. Balzer @balzer-lab.org · 06/06/2025
Go Braunschweig! 🫘
020
Michael S. Balzer @balzer-lab.org · 04/06/2025
🎉🎈Congrats to all ASN 2025 🏆Lifetime & Midcareer awardees! Well-deserved, @ksusztak.bsky.social @rkramann.bsky.social @genetickidneydoc.bsky.social, you are on 🔥!!! #NephSky, #MedSky, #ERA25
ASN Lifetime & Midcareer Awardees 2025
2122
Reposted by Michael S. Balzer
ASN Publications @asnpublications.bsky.social · 31/05/2025
In the May 2025 #ASNKidneyNews Policy Update, explore recent new and existing policy actions from ASN Advocacy that benefit physicians, patients, and researchers. bit.ly/KN1705-16
021
Reposted by Michael S. Balzer
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 27/05/2025
The effect of disappearing data from US public health #OpenAccess viewpoint in @thelancet.com www.thelancet.com/journals/lan... #MedSky #EpiSky
Figure Full season (32-week-ahead) forecasts of influenza hospitalisations in the USA
082
Michael S. Balzer @balzer-lab.org · 18/05/2025
📣Attention #NephSky #MedSky! Inaugural #PeritonealDialysis 🧪research meeting incoming: "1st International Meeting on Cellular & Molecular #PD Research" 📆July 4-5, 2025 @The Nucleus, 🛳️Kiel, Germany 🔗Program & registration: www.pdmeeting.skip-sh.de 👫@ispd.org @dgfn.bsky.social ERA/EDTA
Program & registration: http://www.pdmeeting.skip-sh.de
020